Vol. 13 No. 3 Supplement, 2010

Table of Contents


Current Role of Biological Agents in Colorectal Cancer

Full Article

Hong Kong J Radiol 2010;13(Suppl):S3-9

J Cassidy

Colorectal cancer is one of the most frequently diagnosed malignancies in the world. In spite of recent advances in chemotherapy, the prognosis for patients with metastatic colorectal cancer remains poor. The last decade of ground-breaking research on molecular

Personalised Therapy with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non–small-cell Lung Cancer: Consensus and Controversy

Full Article

ML Zhuo, J Wang

Hong Kong J Radiol 2010;13(Suppl):S10-5

The epidermal growth factor receptor tyrosine kinase inhibitors, including gefitinib and erlotinib, have been proven to provide significant benefit in progression-free survival and overall survival in patients who have received at least one line of prior

Shifting the Paradigm for Maintenance Therapy for Non–small-cell Lung Cancer

Full Article


Hong Kong J Radiol 2010;13(Suppl):S16-21

Systemic chemotherapy has been the standard treatment for advanced / metastatic non–small-cell lung cancer, particularly in those who do not harbour an epidermal growth factor receptor mutation. In the last decade, there was no established evidence to justify

Recent Advances in the Treatment of Lymphomas

Full Article

E Tse, YL Kwong

Hong Kong J Radiol 2010;13(Suppl):S22-4

Malignant lymphoma is a common neoplasm and some are potentially curable if appropriate therapy is given. The use of the monoclonal anti-CD20 antibody rituximab in the management of follicular lymphoma has improved the outcome of patients.

Systemic Therapy for Advanced Gastric Cancer

Full Article

W Yeo

Hong Kong J Radiol 2010;13(Suppl):S25-8

Gastric cancer is the fourth commonest cancer worldwide, with nearly a million new patients being diagnosed with this disease per year, of whom 55% are in East Asia. Regrettably, despite the availability of potentially curative resection, between 50 and 90% of

New Horizons in the Management of Glioblastoma Multiforme: the End of the Beginning?

Full Article

J Tsang

Hong Kong J Radiol 2010;13(Suppl):S29-32

Glioblastoma multiforme is a highly invasive and aggressive brain tumour. It is the most commonly seen glioma with fast-growing features, being a devastating disease with no clear causation and no means of early detection. Less than 10% of glioblastoma

Continuing Therapy beyond Adjuvant Chemotherapy to Optimise Cure in Advanced Ovarian Cancer: a Dream Coming True?

Full Article

RKC Ngan

Hong Kong J Radiol 2010;13(Suppl):S33-41

The GOG111 and OV-10 were pivotal studies published in 1996 and 2000 respectively which established paclitaxel / cisplatin as standard postoperative adjuvant chemotherapy for advanced epithelial ovarian cancers. A second major breakthrough in the ensuing

Cancer Biomarkers and Molecular Theranostics

Full Article

ESK Ma, CLP Wong

Hong Kong J Radiol 2010;13(Suppl):S42-50

Cancer biomarkers have evolved from assays based on proteins, hormones and enzymes to molecular assays based on DNA or RNA. These molecular cancer biomarkers have broad clinical applications in disease screening, diagnosis, classification, offering a